Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalNot applicablepeer-review

5 Scopus Citations
View graph of relations

Author(s)

  • Karina J. Matissek
  • Maristela L. Onozato
  • Sheng Sun
  • Andrew Schultz
  • Jesse Lee
  • Kristofer Patel
  • Piiha-Lotta Jerevall
  • Srinivas Vinod Saladi
  • Allison Macleay
  • Mehrad Tavallai
  • Tanja Badovinac-Crnjevic
  • Carlos Barrios
  • Nuran Beşe
  • Arlene Chan
  • Yanin Chavarri-Guerra
  • Marcio Debiasi
  • Elif Demirdögen
  • Ünal Egeli
  • Sahsuvar Gökgöz
  • Henry Gomez
  • Pedro Liedke
  • Ismet Tasdelen
  • Sahsine Tolunay
  • Gustavo Werutsky
  • Jessica St. Louis
  • Nora Horick
  • Dianne M. Finkelstein
  • Long Phi Le
  • Aditya Bardia
  • Paul E. Goss
  • Dennis C. Sgroi
  • A. John Iafrate
  • Leif W. Ellisen

Detail(s)

Original languageEnglish
Pages (from-to)336-353
Journal / PublicationCancer Discovery
Volume8
Issue number3
Early online date14 Dec 2017
Publication statusPublished - Mar 2018
Externally publishedYes

Abstract

We sought to uncover genetic drivers of hormone receptor-positive (HR+) breast cancer, using a targeted next-generation sequencing approach for detecting expressed gene rearrangements without prior knowledge of the fusion partners. We identified intergenic fusions involving driver genes, including PIK3CA, AKT3, RAF1, and ESR1, in 14% (24/173) of unselected patients with advanced HR+ breast cancer. FISH confirmed the corresponding chromosomal rearrangements in both primary and metastatic tumors. Expression of novel kinase fusions in nontransformed cells deregulates phosphoprotein signaling, cell proliferation, and survival in three-dimensional culture, whereas expression in HR+ breast cancer models modulates estrogen-dependent growth and confers hormonal therapy resistance in vitro and in vivo. Strikingly, shorter overall survival was observed in patients with rearrangement-positive versus rearrangement-negative tumors. Correspondingly, fusions were uncommon (<5%) among 300 patients presenting with primary HR+ breast cancer. Collectively, our findings identify expressed gene fusions as frequent and potentially actionable drivers in HR+ breast cancer. Significance: By using a powerful clinical molecular diagnostic assay, we identified expressed intergenic fusions as frequent contributors to treatment resistance and poor survival in advanced HR+ breast cancer. The prevalence and biological and prognostic significance of these alterations suggests that their detection may alter clinical management and bring to light new therapeutic opportunities.

Citation Format(s)

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. / Matissek, Karina J.; Onozato, Maristela L.; Sun, Sheng; Zheng, Zongli; Schultz, Andrew; Lee, Jesse; Patel, Kristofer; Jerevall, Piiha-Lotta; Saladi, Srinivas Vinod; Macleay, Allison; Tavallai, Mehrad; Badovinac-Crnjevic, Tanja; Barrios, Carlos; Beşe, Nuran; Chan, Arlene; Chavarri-Guerra, Yanin; Debiasi, Marcio; Demirdögen, Elif; Egeli, Ünal; Gökgöz, Sahsuvar; Gomez, Henry; Liedke, Pedro; Tasdelen, Ismet; Tolunay, Sahsine; Werutsky, Gustavo; St. Louis, Jessica; Horick, Nora; Finkelstein, Dianne M.; Le, Long Phi; Bardia, Aditya; Goss, Paul E.; Sgroi, Dennis C.; Iafrate, A. John; Ellisen, Leif W.

In: Cancer Discovery, Vol. 8, No. 3, 03.2018, p. 336-353.

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalNot applicablepeer-review